Page last updated: 2024-08-25

cholest-5-ene-3,4-diol and Neoplasms

cholest-5-ene-3,4-diol has been researched along with Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J	1
de Bruijn, P; de Graan, AJ; de Jonge, E; Mathijssen, RH; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA	1

Trials

2 trial(s) available for cholest-5-ene-3,4-diol and Neoplasms

Article	Year
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides	2020
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. British journal of clinical pharmacology, 2015, Volume: 80, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cytochrome P-450 CYP3A; Docetaxel; Female; Humans; Hydroxycholesterols; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Young Adult	2015

Article

Year

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.

Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1

Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides

2020

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

British journal of clinical pharmacology, 2015, Volume: 80, Issue:3

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cytochrome P-450 CYP3A; Docetaxel; Female; Humans; Hydroxycholesterols; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Young Adult

2015